Lv11
54 积分 2022-11-08 加入
Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma
3小时前
待确认
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting
3小时前
已完结
SHR-8068 plus adebrelimab and bevacizumab for advanced hepatocellular carcinoma (aHCC): A phase 1b/2 study
6天前
已完结
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
18天前
已完结
The 34th Anual Meeting of the Asian Pacific Association for the study of the liver
1个月前
已关闭
Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis
1个月前
已完结
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
1个月前
已完结
Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial
2个月前
已完结
984P Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma with major portal vein tumor thrombosis (Vp3/4): A randomized phase II trial
2个月前
已关闭
Hepatocellular carcinoma with type II–III portal vein tumour thrombosis: treatment using transarterial chemoembolisation and microwave ablation
2个月前
已完结
皖公网安备34019202002308
